Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention MRT-2359, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about QuEEN Platform
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention MRT-2359, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. The 5 average consequence score is below the beat benchmark of 6 in the same window. QuEEN Platform appears in 1 tracked Biotech story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering QuEEN Platform. Shared-story counts are live from our verified record — not editorial picks.
Monte Rosa Therapeutics reported quarterly results highlighting a robust cash position following its $2.1 billion Novartis partnership. The company is accelerating its molecular glue degrader pipeline with a strategic pivot toward high-value immunology indications.